Piece of mineral crystal used to make jewelry
Drs. Hope Rugo and Nancy Davidson discuss the next generation of endocrine therapy in hormone receptor-positive breast cancer – SERDs, SERMs, CERANs, and PROTACs – and challenges relating to the optimal sequence of therapeutic options. TRANSCRIPT Dr. Hope Rugo: Hello, I'm Dr. Hope Rugo, your guest host of the ASCO Daily News Podcast today. I'm a professor of medicine and director of breast oncology and clinical trials education at the University of California San Francisco's Comprehensive Cancer Center. Hormone receptor-positive (HR+) breast cancer is the most common subset of this disease and breast cancer is the most common cancer diagnosed in women worldwide. Endocrine therapy (ET) is the cornerstone of management in hormone receptor-positive breast cancer and may involve suppressing estrogen production with aromatase inhibitors in the cancer cell itself, or directly blocking the estrogen receptor pathway through selective estrogen receptor modulators, such as tamoxifen, or the injectable selective estrogen receptor degrader, fulvestrant. However, despite the availability of these therapies, the largest unmet need lies in treatment of HR-positive HER-negative disease lies after progression on endocrine therapy. On today's episode, we'll be discussing the emerging generation of endocrine therapies in breast cancer, some of which were designed to overcome common mechanisms of endocrine resistance, and the challenges relating to the optimal sequence of therapeutic options. Today, I'm delighted to welcome the world-renowned breast cancer researcher, Dr. Nancy Davidson, to the podcast. She's a professor and the executive vice president for clinical affairs at the Fred Hutchinson Cancer Center and professor of medicine at the University of Washington as well as past president of ASCO and AACR. You'll find our full disclosures in the transcript of this episode and disclosures of all guests on the podcast can be found in our transcripts at asco.org/DNpod. Nancy, it's great to have you on the podcast today. Thanks so much for being here. Dr. Nancy Davidson: Thank you so much, Hope, for the opportunity. Dr. Hope Rugo: You've done incredible work in the area of treating HR+ disease, but also in understanding some of the agents and pathways that are most important to our understanding of how we treat and really think about developing new drugs for HR+ breast cancer. The first generation of anti-estrogen drugs really included selective estrogen receptor modulators, but now we have a new generation of these anti-estrogen drugs. And there's also orally administered selective estrogen receptor degraders, so-called SERDs, that we hope someday will be an alternative with already one approved for the injectable SERD, fulvestrant. But there's a whole additional class of drugs, complete estrogen receptor antagonists, referred to as CERANs, and proteolysis targeting chimerics, PROTACs. These agents are all at various stages of development in both early and metastatic settings and really represent, I think, a confusing array of different treatments that are being studied, some of which of course are approved. Nancy, it would be great if you could tell us some about these exciting new agents, starting with our approved drugs and moving on to the agents that we're studying in clinical trials. Dr. Nancy Davidson: Hope, this is a terrific example of how basic science has really begun to inform clinical practice. For us as breast cancer practitioners, it was really easy for a long time because we only had tamoxifen. And then things like the aromatase inhibitors as a means of decreasing the estrogen ligand came into practice, as did fulvestrant, as you mentioned, a selective estrogen receptor degrader. Thanks though to a lot of understanding about estrogen receptor biology, and specifically, the discovery about a decade ago of estrogen receptor mutations, something that we didn't think exist ed for a long time, but which we now know exists in maybe a third to a half of breast cancers after exposure to aromatase inhibitors, that's led to really an explosion, this alphabet soup of possibilities that you talked about. SERMs, selective estrogen receptor modulators, tamoxifen is the classic one—something that acts as an agonist and as an antagonist, depending on the tissue. The SERDs, the selective estrogen receptor degraders, lead to estrogen receptor destruction. Fulvestrant is the classic example of this right now. But we're very excited that a second one has been FDA approved. That's elacestrant that was approved earlier this year, and it has specifically been developed to try to target those estrogen receptor mutant breast cancers because those are the ones that are particularly resistant. So that's the first of this new generation of SERDs that's coming on the market, has come on the market. As you say, a key advantage there is that it's oral, unlike fulvestrant, which requires 2 monthly injections and is very, very inconvenient and uncomfortable for patients. Other SERDs are coming along. I think another one that is well along in clinical development is giredestrant, which is in the same family and being tested in clinical trials of the classic varieties. It's been tested in a window trial, looking at its ability to down-regulate Ki67. It's being tested against standard of care in first-line metastatic breast cancer. And there are some studies that are going to begin looking at it in the adjuvant setting as well. There are other members of this particular family, but I think that elacestrant is the one that we have at our fingertips right now, and giredestrant is one that's certainly coming along in clinical trials, and we should look forward to those results. For those who are interested in the giredestrant, the trials in question right now that are going on are persevERA, which is in stage 4 breast cancer, and lidERA, which is in the adjuvant setting. Now that's one new category, or it's an old category with a new twist. A second is these agents that are called complete estrogen receptor antagonists, CERANs, as you talked about them. The key here is that what they do is, the estrogen receptor has a couple of domains, and in particular, it has 2 different activation domains, AFT1 and AFT2. And these CERANs are complete estrogen receptor antagonists, so they block both of those domains. And the hope would be that they might end up being more effective than the other agents that we have available to us right now. So those are also in clinical trial at the present time, and we're waiting to see whether or not there's going be any value in that particular area that's going to able to go forward for us. Another area that I think we want to talk about is the PROTACs, as you mentioned. These are proteolysis targeting chimeric entities. So, this is a kind of a complicated situation where you have a kind of bivalent situation where you have something that binds both to the estrogen receptor and then also to E3 ubiquinase. So, it leads to degradation again of the agents; that's another area for us to be watching. And then finally the SERCAs. So those are the selective estrogen receptor covalent antagonists, and what they do is they bind very specifically to a cysteine 530 that exists in the estrogen receptor but not in other steroid receptors. So that's where the selective part of this comes along. Now these are all in various stages of clinical investigation. Some of them are pretty early at this point, but I think the ones that are well established are elacestrant, giredestrant is coming along as we just talked about. Camizestrant is also coming along through the SERENA series of trials, and imlunestrant is also coming on through the EMBER series of trials. Hope, I would also be remiss if I didn't go back to an old drug that's a new drug, and that's lasofoxifene, which is also in the SERM family. Those who have been in our field for a while will remember that lasofoxifene was actually originally kind of tested in the prevention setting, where it seemed to have some activity. It came back into our interest because it has really strong activity against estrogen receptor mutant breast cancer models in the laboratory. And as a consequence of that, it's coming back into the clinic through a series of trials that are called the ELAINE trials, where we're looking to see whether or not it might also be better than fulvestrant. It too is an oral agent, so that's a real plus for us, and the first set of ELAINE trials would suggest that there's some nice activity without a lot of toxicity. So, lots going on in this field. You know, I think for all of these things, obviously, we're also working very hard to think about the toxicities. All of these, as I recall, are oral agents. So that gets rid of 1 huge toxicity, which is you don't have the need for some sort of injection. But they all do have some side effects. Frequently, [the toxicities] are like GI side effects or fatigue. In a couple of cases, there might be some concern about cardiac arrhythmias, but I think GI turns out to be one of the most important things that we have seen in some of these trials. Generally, it's very well tolerated, though. I think another important question, which I'm sure is in your head and is in mine, is that how are we going to integrate these into what we already have? And so, I think a lot of the work right now is looking at patients who have already received an aromatase inhibitor plus a CDK4/6 inhibitor and are now going on to one of these new agents. But you might wonder, if they turn out to be effective and well-tolerated, whether they too should be perhaps combined with CDK4/6 inhibitors in place of the aromatase inhibitors or the fulvestrant that we use now. So, I think that we can imagine that those clinical trials are either in progress in some cases or will be coming on as we try to think about how to integrate these new approaches into our existing standard of care, which is already quite complicated, right? We've gone far from tamoxifen, which was good for everybody, to now a really complex algorithm about how we think about hormone therapy, both in early breast cancer and in metastatic breast cancer. Dr. Hope Rugo: Well, that was a fabulous discussion about the new agents and our existing agents and both the exciting aspects, as well as the challenges. One question that comes up, I think a lot, and this is of course a huge question in many ways, but for ER-positive metastatic breast cancer, where these drugs are first being tested, maybe we'll talk about that first. There's one trial at SERENA-6, looking at camizestrant in patients who have developed evidence of an ESR1 mutation in circulating tumor DNA, who are on first-line therapy with an AI and a CDK4/6 inhibitor. What do you think about that study and where do you think that progress might go? Of course, that's based on data from another trial, which wasn't definitive, but suggested, had sort of a suggestion, you know, without studying the sequencing in detail that maybe you would have improved progression-free survival with that approach. Dr. Nancy Davidson: Yeah, by which you mean the idea of monitoring pre-ESR1 mutations and circulating DNA and then making therapy changes based on that? Is that what you're talking about? Dr. Hope Rugo: The PADA-1 trial, yes, and that led to this huge SERENA-6 trial, which of course is now accruing. Dr. Nancy Davidson: So, you know, we would love that, right? I think that obviously breast cancer for many years has been interested in trying to have circulating markers that we could use to help to guide our therapy in a more meaningful way than we have in the past. And I think that the trial that you've talked about is certainly one that's trying to make that see whether that's a possibility for us based on information like the PADA trial. I'm hopeful it's going to work out. I would say, let's see what that looks like, whether it's going to be useful or not. It seems to me in some cases, some of these trials have not been quite what we hoped for, but I don't think we necessarily had the molecular techniques or the sensitivity, nor did we necessarily have other things to move to because, you know, those two approaches require both a really good test, but also the ability to use the test to define a new therapy that's going to lead to improved patient outcomes. And I think that these are ingredients that we now have available to us at our fingertips more than we did, say, a decade or 2 decades ago. Exciting approach. Dr. Hope Rugo: I do think there's a lot of challenges inherent in this process, monitoring blood on a regular basis and following up and then randomizing based on results. But I think [SERENA-6] is an incredibly important trial, as you have mentioned, to try and think about moving past using circulating tumor cells, which didn't work, to just change blindly to the next therapy, but more have a rational reason to change to a drug that may be more effective before the disease itself progresses. And just for our listeners, the unique aspect of trials like this in SERENA-6 is that you change therapy before you have evidence of disease progression, but only this molecular evidence of a mutation that is associated with resistance to the therapy you're on. So, it's a really important question. We'll see what happens, as you mentioned, sometimes we're not clever enough to really get around the fact that there are multiple mutations driving resistance in this setting, so we'll see how straightforward this is. The question also comes up, and I think that's a question with many of these trials now, is they're randomizing patients after a progression on an AI and CDK4/6 inhibitor to receive the novel endocrine therapy or fulvestrant. One of, I think, the concerns of treating oncologists is that then you're sort of eliminating the possibility of a targeted agent in that setting. And of course, we have new targeted agents we're studying as well, AKT inhibitors and new inhibitors of the PI3 kinase pathway. So, the newer trials are now combining, as you mentioned. There's a lot of concerns about drug-drug interactions here and how you might really combine them. And then there are triplet studies looking at CDK4/6 inhibitors, oral SERDs primarily, and pi3-kinase and CDK4/6 inhibitors. What's your thought on these and will they really help to move the needle forward? Dr. Nancy Davidson: I think that's a really interesting question, Hope, is whether or not we're going to find that combination therapies from the get-go are the way to go, or whether we're going to end up having to use maybe more serial therapies. Because not only is it a question about whether or not you can tackle all of these different resistance mechanisms simultaneously, but I think the other question is, as you say, are there negative drug-drug interactions, and are there toxicities that are intolerable? Although these are targeted in all cases and they're relatively benign in terms of side effects from the breast cancer perspective, they're not devoid of toxicity. And so, I think that's going to be another issue for us – whether they're well tolerated during the time that patients are taking them. I guess the other thing I always think about, Hope, is that it's hard to know about value of cancer care, but you know, we are talking about agents that are not inexpensive. You know, when you think about the financial toxicity, in addition to the side effect toxicity that you and I just talked about, trying to think about what that value is going to look like is going to be very important for us. Also, as somebody who worked for a long time in the lab and in the clinic, you know, there are an infinite number of combinations that you and I could think about that are rational. And so, the question is, how are we going to pick the ones that are the most rational, if you will, the ones that seem to be the most promising, and take them forward into clinical trials? Because patients are our most precious resource. And so, we want to make sure that we are bringing forward only those things that really seem to have a very strong foundation and the opportunity to improve outcomes over time. Tough, tough question for us to try to think about, as you've talked about. The other thing is that, you know, these trials are not only for postmenopausal women, who are the majority of patients, but we also want to target them to premenopausal women. So, in those women, we're also looking at using an LHRH agonist on top of this, right, because many of these things are really at least so far designed for the postmenopausal state. So stay tuned. Lots of work going on. I think one of the interesting things will be making the leap from using these in metastatic disease at time of progression to taking them forward into the early breast cancer space. And several of the agents are now beginning to do that because of very strong preclinical and clinical data to date. Dr. Hope Rugo: So, we have new agents that we're studying in the metastatic setting, and we've seen a trend to move fairly rapidly from phase 1B trials directly into phase 3 trials, because as you pointed out so clearly, there are a number of drugs in this setting, and we don't really know not only which agent is better, but even what class of agents is better. So, as we move more quickly from phase 1B to phase 3, the question comes up about how we're going to study these agents optimally in the early-stage setting. They, I think we all thought that maybe changing based on ctDNA evidence of a mutation might be an approach, but that's complicated. A big question for you is whether or not you think that's ready for prime time as it's being marketed as such. And then the second question is really, are we better changing our whole approach upfront in high-risk disease or should we wait until after patients are exposed to their endocrine therapy and then switch as we go along; the EMBER-4 trial is looking at that switching approach? Dr. Nancy Davidson: Yeah, I think that this is obviously the billion-dollar question for many companies and for many of us as investigators. I don't know that I have a crystal ball into what the best approach might be. We know that already some of these have been abandoned. For example, amcenestrant. So, I don't even have to learn how to say it because it has been abandoned. It did go to phase 3, as you pointed out, in the advanced setting, looking at it with palbo vs letrozole plus palbo, and it didn't really show a whole lot that the company wanted to pursue. So, I think that sometimes these things are going to be abandoned based on the metastatic setting, which is a large trial, and that's a trial where obviously it might be a little easier to the circulating markers, as you talked about, than maybe in the early-stage breast cancer setting. I think that probably these early-stage trials are going to end up being big; they're going to have be clean. I'm guessing that most companies and most investigators will want to target them towards high-risk individuals, as you talked about, for 2 reasons. One is that ethically, I think we feel more comfortable with that. These are individuals where standard therapies are maybe not serving them as well as we would like and where we have information to think that we can at least have equipoise about a new approach. And the second is that from a trial design point of view, the event rate is likely to be higher, and therefore you might get answers earlier and with a smaller clinical trial. So that's where I suspect we're going to go. But it's a challenging question, and I think that many investigators and many companies are really trying to struggle with that right now because we do have so many options. And we're not quite sure how to, first, develop these new drugs, but then really importantly, put them in the context of our existing drugs. And as you say, we're also simultaneously trying to develop superior molecular or circulating markers to guide us. So, there's so many variables that are going on right now in this field that, from my point of view, itmakes it really exciting, but it also makes it pretty complicated, both for investigators and for pharma as we try to think about how to position these going forward. But what a great problem to have, Hope, because remember when you and I started in breast cancer, pretty much all you needed to know was tamoxifen. And I think you and I also probably started at the tail end of the time when we were using androgens and progestins and agents that now have basically completely fallen out of favor. Dr. Hope Rugo: Estrogen Dr. Nancy Davidson: Estrogen, yeah, and your side effect profiles were not as good. So, it's a good problem to have. It's a nice situation when science can inform our clinical investigation, our clinical practice. Dr. Hope Rugo: Yes, I think it'll be fascinating to see where we end up at the end, but of course, the complexities of this include the fact that sometimes just the clinical trial design leads to a less than positive result because of the way the trial itself has been designed, which I think is the nice part about moving these earlier into treatment of high-risk disease, but also brings up the question of all sorts of areas we're not really a place to discuss today, like how the statistical design is made, et cetera, that can sometimes result in poor evaluation of excellent agents. One of the questions that comes up, and you brought this up earlier, which I think is really important, is that we are in the era of combining our endocrine agents with targeted agents, and, oral agents, in a fascinating way, really bring up drug-drug interactions in a way that the injectable fulvestrant hasn't, and aromatase inhibitors were kind of quiet on the impacting metabolism, unlike tamoxifen. But we are seeing some drug-drug interactions and certainly the discussions about using these agents may include the question about whether or not you're having more diarrhea or nausea or fatigue or one drug causes photopsia, flashing lights, things like that. Keratitis is becoming a new toxicity to follow. How are we going to figure out how to sequence these drugs and are they only going to work better all of them as a class in patients with ESR1 mutations in their tumors? Dr. Nancy Davidson: I think we don't know the answer to the second question yet. That's something that really needs to be sorted out. Even if they do, that's still a really important subset of patients, assuming that we continue to start with the aromatase inhibitors, right? That's where those things really seem to emerge right now. I don't know how we're going to figure those things out. I guess that I'm hoping that maybe a couple of agents in these classes will become kind of the lead agents. And so, we'll be able to do this work with a handful of things as opposed to a whole array of things. But we'll see. I think that even within classes, obviously, these agents are going be slightly different, probably. And so it may be that one member of a class may be slightly better from a, maybe not from an efficacy point of view, but from a toxicity point of view. And we'll just have to see how it goes. I don't think I have any magic answers about that. Dr. Hope Rugo: Yes, it'll be interesting to see whether or not the agents work in sequence too. You know, could you use a PROTAC after an oral SERD, for example, or a CERAN? That'll be fascinating to see. Dr. Nancy Davidson: I'm hoping that preclinical modeling may help with that a little bit, though of course we all know that there are plenty of things that do well in preclinical models, GEMS and rodent models and PDXs, and sometimes those things translate nicely into clinical practice, but sometimes they don't. Dr. Hope Rugo: You mentioned, Nancy, that when we started out, that it was a fairly simple decision about what endocrine therapies, and we ran out very quickly. We're seeing some of those old classes come up with new agents. And you mentioned lasofoxifene, the oral SERM that seems to have some benefits and works in the later-line setting and also can be combined with a CDK4/6 inhibitor; [and also] has data with abemaciclib. There's also a new androgen receptor agonist, enobosarm, that's being tested as well. Do you think that these older mechanisms have a future as well? Dr. Nancy Davidson: I do. I think that because we'll be able to understand the biology better than we did in the past. A lot of our hormone therapy was pretty empiric several decades ago. But I think with better understanding of mechanisms and better understanding of what the patterns of resistance might be for a particular tumor, that we might be able to think about those things. You're right that there's a whole parallel universe right now in androgen receptor targeted therapies that we're not talking about today, both in perhaps in hormone-responsive breast cancers, but also in triple-negative breast cancers in a certain subset. And so that's an area where we probably need to be watching what our prostate cancer colleagues are doing as they develop these agents and thinking about where they might mechanistically make sense to apply in the breast cancer field. It won't be the first time that we've received insights from them because remember, prostate cancer people knew about androgen receptor mutations a really long time before we figured out that they existed in estrogen receptor as well. So, there's a nice cross talk, I think, between the prostate cancer field and the breast cancer field in that regard. Dr. Hope Rugo: That's an excellent point. And we learn a lot from our colleagues studying other malignancies, and prostate cancer has been a big area there for us and hopefully will help us with studying these agents because there's different toxicity profiles, of course, as well. And then you mentioned the approval of elacestrant, the first oral SERD to have regulatory approval, and it's approved in patients who have ESR1 mutations in their tumors. We're also studying it in the ELEVATE trial in combination with all of the different targeted agents, the CDK4/6 inhibitors, mTOR inhibitor, everolimus, and the PI3 kinase inhibitor, alpelisib, to really try and understand how these can be optimally combined. Would you check for ESR1 mutations at diagnosis of metastatic disease, or would you do this more after progression or start of progression of disease on an aromatase inhibitor? Dr. Nancy Davidson: I tend to be a conservative, Hope, and so unless there's a clinical trial that might be able to be considered, I would tend to check it only after progression on the aromatase inhibitor. But I think some people are earlier adopters, and I suppose it's possible that they might want to know from the get-go. Having said that, I do think elacestrant has an approval after aromatase inhibitor, as I recall. So, presumably the patient would have to have that exposure before you would be able to act on the ESR1 mutation by administering the oral SERD. This is also a new area that may well change with time, right? You know, as we develop different agents, as the agents have different requirements or different indications, and as we perhaps have better tests, it may be things that we don't do routinely now will become very routine in the future. And perhaps in series like you talked about in a serial fashion. Dr. Hope Rugo: Absolutely. I think that's a really important comment about how we're going to think about treating hormone receptor positive disease and potentially, you know, we have new chemo options, of course, not part of our talk discussion today and antibody drug conjugates. So, the future is certainly challenging in terms of understanding this appropriate sequencing. We need data, but it's exciting to have these options. As you pointed out, this is this is a great problem to have, you know, too many drugs with efficacy to try and understand how to use these in the most appropriate way. And as you also pointed out, the use in young women is particularly important. Whether or not you need to suppress the ovaries with all of these new agents is going to be important to understand as well as a next step. I don't know if you have specific thoughts on that area as well. I mean, that may reduce toxicity for younger women. Dr. Nancy Davidson: I guess our approach right now has been to suppress them, but I agree with you; you wonder if you look at some of the mechanisms of action, whether that's really a requirement biologically and medically, or whether it's something that's kind of a leftover from the approval process. You know, that for the drug approval, these women were suppressed. I think we need to work that out because that's another area where certainly women could have ovaries removed. That's pretty straightforward, although it requires a surgical procedure. But otherwise use of LHRH agonists continues to be injections, right? And so, if we're trying to minimize convenience or maximize convenience and minimize toxicity for women with any stage of breast cancer, anything we can do, it seems to me to eliminate an injection is going to be a good thing. So important for us to be able to work that out as well, even though numerically it's a smaller number of women, it's obviously a very important number. population of women. Dr. Hope Rugo: Last question for you. One question that comes up and sent to me and panels all the time is, if you have done your next generation sequencing and you see an ESR1 mutation and a P13CA mutation, what do you prioritize in terms of your choice of treatment, because we have the choice of either using elacestrant or a fulvestrant in combination with an agent targeting the PI3 kinase pathway? Dr. Nancy Davidson: I don't know that there's a right answer to that medically right now. So, when I talk about it with patients, I suggest to them that it's probably not one or the other. It's kind of the question of which one to use first. So, we talk a little bit about side effect profiles. We talk a little bit about patient preference and neither of these drugs is devoid of problems, but sometimes patients have pretty strong feelings about which set of side effects seems the least unattractive to them or the possibility of having those side effects. And I know that if one isn't well tolerated, you can swap over to the other. Dr. Hope Rugo: Absolutely. I think that's a very important way to think about next therapies in our era of not really knowing what's right. And this idea of shared decision-making is so incredibly important. Nancy, thank you so much for sharing your insights and knowledge with us today. I could talk to you for hours about this. Dr. Nancy Davidson: Hope, thank you so much for the opportunity. It is an exciting area and I really enjoyed talking with you about what we know and the many things that we don't yet know, but we're working on. Dr. Hope Rugo: Indeed, it's certainly an exciting time. Thank you to our listeners for joining us today. And thanks to the ASCO Daily News Podcast for highlighting this important area. You'll find a link to all of the studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Thanks so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers: Dr. Hope Rugo @hoperugo Dr. Nancy Davidson Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Hope Rugo: Consulting or Advisory Role: Napo Pharmaceuticals, Puma Biotechnology, Mylan, Eisai, Daiichi Sankyo Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Genentech, Merck, Daiichi Sankyo, Sermonix Pharmaceuticals, AstraZeneca, Gilead Sciences, Astellas Pharma, Talho Oncology, Veru, GlaxoSmithKline, Hoffmann-LaRoche AG/Genentech, Inc Travel, Accommodations, Expenses: Merck, AstraZeneca Dr. Nancy Davidson: No Relationships to Disclose
Less than 200 days to go until the world is saved!MC and A Plus officially start the Fall season on The BlkPrint with mixed feelings -- is it a time to celebrate or a time to panic as the year winds down? Hear their current thoughts on their hometown team headlines as the Washington Comma--err, Football Team start decent for the season and the Miami Heat stay stranded on Day 88 of Lillard Gate. Also tune in to hear the latest in the Recut Rotation, highlighting huge news for Lil Wayne's mixtape catalog, Future's newly released discography and the 10-year anniversary of Drake's 'Nothing Was the Same'. ★ Support this podcast on Patreon ★
In this episode we're joined by Elijah aka Coach Westbrook. He's a former college football athlete for NC A&T State University, an athletic trainer and now gym owner. Elijah speaks on his new gym “The Dawg Pound” and tells his story as a performance coach. Gems were dropped on healthy life topics and more! Join us for some good conversations and even better laughs! Follow us! @wastedtwentiespod on Instagram and TikTok. Sponsor: Prime Fitness @ The Dawg Pound Instagram: @coachwestbrook_ Website: https://linktr.ee/coachwestbrook Feel free to reach out to us via email at email@example.com with sponsorships or topics you'd like us to cover. Book DNT Studio for your photography, podcast & content needs! https://linktr.ee/dntstudio?utm_source=linktree_profile_share<sid=c5b20652-2c70-49ad-a78b-00f38fd07423 --- Send in a voice message: https://podcasters.spotify.com/pod/show/wastedtwenties/message
In today's episode of Em's Gems, I am talking about how to set your business and yourself up for success for next year! I explain how to work backward from the end of the year to set goals, why each quarter is like a mini client journey, the key to working smarter (not harder) to avoid exhaustion and burnout, what it really takes to build out a sustainable business, why taking an hour for yourself isn't going to tank your biz and so much more! Join Em's next livestream every Friday in her free Facebook group. You can ask her questions LIVE! https://www.facebook.com/groups/380383430629510 DM ME ON INSTAGRAM: https://www.instagram.com/emmhaas/
Here are your cliff notes for all-things connection & education from the month of September, plus a sneak peek into October and our upcoming launch. If you haven't already checked out this month's episodes, take a listen!! My take away gem for this month: There is nothing more important than connection - no learning will happen until kids feel safe and in community! RESOURCES Dr. Amy's Newsletter Learning Collaborative - The ConnectED Collab Invitation Dr. Amy Youtube FREE DOWNLOADS Top 10 Guiding Principles When Working with Children & Families Start Creating Boundaries Handout & Script Finding Calm to Prevent Overwhelm Don't Forget! Follow Dr. Amy on LinkedIn, Facebook, and Instagram For more information visit www.doctoramyllc.com
On Episode 108, today's guest hails from Tampa, Florida. He's a Beatmaker, Live Performer, Quadruplet, Audio Technician, Music Gear Technician and more. Please welcome Matwithone.T to the show. Enjoy and check the links below!During this episode, we chopped it up about his music journey, inspirations, aspirations and more. As a Quadruplet, his moniker is from his amazing Mother who is celebrating her 50th Birthday forgot their was only one T in his name. His pops (The Human Jukebox) had 200GB of music & siblings listened to a lot of music from a lot of genres like R&B, Rock DMV, Trance which led to his musical genre-bending. Always music adjacent in 2019, The Brevard Music Center he learned how to mic up the instruments for orchestras. He got a cracked Ableton and went down the rabbit hole of learning. Watching Tajima Hal La Mellotron beat set he saved his money and purchased a SP404SX, MPC1000 & Ableton. He names his Greatest Beats of All Time from "Feather" from Modal Soul by Nujabes, "For a while" from Tones by Tajima Hal & "Fly Like a Butterfly from Jetset Radio Future by Hideki Naganuma. He names his Beatmaker/Music Producer Superheros like YoCiscokid, Friendkerrek, Suma.wav, Deek Beats, StillDo, Abnormalisdope, SamDrumo, Bundo, JFilt, Kumachen and Argenis Santos. Matwithone.T. creates music using different samplers like Ableton, SP404SX, MPC1000 and more.Matwithone.T left crazy jewels, inspiring words for Beatmakers and detailed what's in store for the rest of 2023 & 2024.Matwithone.T's Gems:1. Getting involved in local beat scene and learn what it takes to put an event together 2. Watch Le Mellotron and Tajima Hal Beat Set3. Keep going even though you may feel discouraged4. Get a good group of fans and nurture that relationships5. Its not a race its a journey. Enjoy the journey6. Create a live set poster which includes your artist QR codesIntro Track: 'Growin' Painz" from Growin' Painz by B4LasersSocial Media: @matwithone.T Website: https://linktr.ee/matwithonet Support the showSupport the showEdited, Mixed and Mastered by GldnmndPodcast Website Link: The Rec Show PodcastNEW!!! TheRecShowPodcast Music Playlist Available Here
We're back to serve you up a special slab of great new rock and metal tunes from killer new artists with Fresh Blood! In this edition, Chris is delivering great tracks from The Sunset Drip, Iron Void, Midnight Vice, The Lazys, and Samarkind. All five tracks are killer and run the gamut of the genres. Aaron's bringing you excellent new tracks from Seven Ravens, Roadwolf, The Cold Stares, Wanted, and The Gems. It's a great collection of tunes to discover. If you hear something you like, be sure to support the artists through purchasing albums, merch, following them on social media, and watching for them on tour near you. The future of rock depends on YOU! We hope you enjoy Fresh Blood for September of 2023 and SHARE with a friend! Decibel Geek is a proud member of the Pantheon Podcasts family. Contact Us! Rate, Review, and Subscribe in iTunes Join the Facebook Fan Page Follow on Twitter Follow on Instagram E-mail Us Subscribe to our Youtube channel! Support Us! Buy a T-Shirt! Donate to the show! Stream Us! Stitcher Radio Spreaker TuneIn Become a VIP Subscriber! Click HERE for more info! Comment Below Direct Download Learn more about your ad choices. Visit megaphone.fm/adchoices
Hello, hello everyone and welcome! This week we follow up on DC Heroes and Villains, who actually gave us something that's “Coming Soon,” and now the race is on to find your alliances. Elseworlds, we talk about the heavily discounted gold gem sales, we discuss Zatana's boobies, and which Star Wars shows do the All Stars watch? Tune in right now… same AAD time… same AAD channel… a new episode is one click away!
Jake has been diving into the Starfield via Microsoft's magical Xcloud, and Ryan has been watching some GEMS of horror movies. That's right, we're talking about The Gate, we're talking about My Bloody Valentine, we're talking about Evil Dead Rise, we're talking Joe Dirt and Joe Dirt 2 (wait maybe those last ones aren't in the same genre). So sit back, and relax as we take you to some far away places and realties in this episode! Hosted on Acast. See acast.com/privacy for more information.
In this Episode I sat down with Ty Mosley, a fellow coach I have crossed paths with many times sharing courts in ymca's and local parks. I wanted to learn more about his story and how he got into coaching. This industry is not for the weak because of the countless hours that go into preparation. As a coach you have a bit of insanity if you choose the profession. What drives Coach Mosley? A love for the game, listen in as he shares his story on how he got into coaching at one of best prep schools in New England. Keep tuning in for new episodes every Monday for that fire content from Coach Beas and his guests dropping GEMS. Don't forget to subscribe, rate, and review the podcast. We want to hear from YOU! DM @beasttrainingonline or @coach_beas on IG with any questions, comments, or feedback. For more about Coach Beasley and the B.E.A.S.T Podcast check out beasttrainingonline.com --- Send in a voice message: https://podcasters.spotify.com/pod/show/beastpodcast/message Support this podcast: https://podcasters.spotify.com/pod/show/beastpodcast/support
The video version mentioned might not be out quite yet on the FUT Weekly YouTube Channel, but it won't be long if you'd rather wait for that! 1 million coins? What about 1 million browser tabs? Josh, H00bear and Ben have been scouring the FUT.GG database over the last few days so you don't have to. They 02:08 Womens Players Database Impact 03:15 Pack Weight 06:43 What Do You Look For Early On 11:23 Starting Formations 13:33 Our Database Gems 48:58 TOTW Changes 52:27 Heroes Enter the 36k FIFA Point competition, get this week's supporter episode — 2 podcasts every week — and keep FUT Weekly going (for just £3 a month) by becoming a Patreon over at bit.ly/morepod Learn more about your ad choices. Visit megaphone.fm/adchoices
01 Difference (Original Mix) - Binary Finary And Jose Amnesia Pres Cloudbreak [Enhanced Progressive] 02 Thrill (Original Mix) - Ernesto vs. Bastian [High Contrast Recordings] 03 Part Of Me (Solar Energy Remix) - Solarstone feat. Elizabeth Fields [Solaris Recordings] 04 Lost (Club Mix) - Sunlounger feat. Zara [Magic Island Records] 05 Always The Sun - Richard Durand [Magik Muzik] 06 Made Of Sun (Stoneface & Terminal Remix) - Kyau & Albert [Anjunabeats] 07 Like A Waterfall (Eco Remix) - Solarstone feat. JES [Black Hole Recordings] 08 Elf (2001 Returning Mix) - Bart Claessen [Anjunabeats] 09 Off The World (Gareth Emery Remix) - Martin Roth & Alex Bartlett [Vandit Records] 10 Antarctic Night (Original Mix) - Blue Tente [Sensate Recordings] 11 The Path (Original Mix) - Andy Tau [Infrasonic Recordings] 12 Two Against The World (Original Mix) - Sindre Eide [Enhanced Recordings] 13 Sunset On Ibiza (Above & Beyond Mix) - Three Drives [Mid-Town Records] 14 Stormy Clouds (Original Mix) - John O'callaghan [Discover Dark] 15 Fields of love (Dan Stone remix) - Kamil Esten [Tool Trance]
Welcome back to CFBDynasty's Week 4 College Fantasy Football Rankings! In this week's episode, we're not holding back as we dive into a little vent session about who's been downright terrible in college football lately. But that's not all – we've got a jam-packed show with elite Week 4 matchups, the latest news and notes, hidden waiver wire gems, top streamer picks, and much more.
In this episode of Em's Gems, I am talking to the magical Bridget James Ling, an online business coach helping women build million-dollar movements. This Queen knows how to have fun and bring out the inner child, and I am so excited for Bridget to expand on why she built her business, how she integrates freedom and fun into her offers, what her super simple 4 step business strategy is, her unique take on embodiment, what Freedom Queen means to her, and why she's so passionate about spreading the message to just move –plus so much more! Follow Bridget on IG @bridgetjamesling Join Em's next livestream every Friday in her free Facebook group. You can ask her questions LIVE! https://www.facebook.com/groups/380383430629510 DM ME ON INSTAGRAM: https://www.instagram.com/emmhaas/
Kia Ora! Finishing RPG A DAY 2023 eventually. Because I have to share what I recorded for you all. And because I have more to share but this episode is blocking the feed haha. Hope you enjoyed the RPG feed and see you again very soon. Thanks to my Gems listening out there: Jason, Barry, Lieran, Ezequiel, Violet, Joey, Samsara, Karl and BJ. Become a Gem by visiting https://www.patreon.com/jewelsfromnz Send messages thru Glitter Discord or email on firstname.lastname@example.org Find me under @JulzfromNZ on Instagram, Facebook and @julzburgisser on Twitter as well! Aroha nui. Ka kite anō. Xx --- Send in a voice message: https://podcasters.spotify.com/pod/show/jewelsfromnz/message
Would you hire yourself? Hear from Charles S. Price, one of the five most influential commercial litigators in Arizona share valuable GEMS on rewiring the white-collar mind. WHO IS CHARLES S. PRICE? Charles is a civil litigator with the law firm Dickinson Wright in Phoenix, as well as what he calls a “Rewiring Coach” for lawyers and other professionals. He has practiced law for more than 40 years and is listed in the current edition of “Who's Who in American Law”. Mr. Price has been recognized by AZ Business Leaders magazine as one of the five most influential commercial litigators in Arizona. He is also the author of Rewiring the White-Collar Mind. Jack Canfield, the co-author of the famous Chicken Soup for the Soul series, says, “I love this book! If you're feeling overwhelmed and unhappy, you need this book.” CHARLES'S CALL TO ACTION Write to me at email@example.com about coaching. Purchase Rewiring the White-Collar Mind at Amazon. https://www.charlespriceesq.com/ CALL TO ACTION Subscribe / Follow GEMS with Genesis Amaris Kemp podcast & YouTube channel, Hit the notifications bell so you don't miss any content, and share with family/friends. GENESIS'S INFO https://genesisamariskemp.net/genesisamariskemp If you would like to be a SPONSOR or have any of your merchandise mentioned please reach out via email --- Send in a voice message: https://podcasters.spotify.com/pod/show/genesis-amaris-kemp/message Support this podcast: https://podcasters.spotify.com/pod/show/genesis-amaris-kemp/support
A conversation with Los Angeles County Museum of Art curator Diva Zumaya about the new exhibit “The World Made Wondrous: The Dutch Collector's Cabinet and the Politics of Possession” on display now through March 3rd of next year. Zumaya, who is the Assistant Curator, European Painting and Sculpture at LACMA, has brought together over 300 objects for the exhibit, including paintings, prints, sculptures, precious stones, shells, and taxidermy in order to recreate a fictive 17th-century Dutch collector's cabinet. The result is a dialog about the political and colonial histories of European collecting practices in the 17th century which highlights problematic policies, beliefs and visual representations.https://www.lacma.org/art/exhibition/world-made-wondrous-dutch-collectors-cabinet-and-politics-possession
On Episode 107, today's guest hails from Chicago Illinois. He's a DeeJay, Producer, R&B Lover, Lazy Corporate by day, 90s Sitcoms / Anime fanatic and more. Please welcome Cozy Cole G. to the show. Enjoy and check the links below!During this episode, we chopped it up about his music journey, inspirations, aspirations and more. Cole G. grew up in Detroit, Michigan & Chicago, Illinois watching his amazing Great-Grandmother (Juanita Harvey/102 yrs old) play the piano, his Mother (Singer) and Father both music lovers and his older brother (Blaksmith) exposing him to more conscious music throughout the 90's & 2000s. He got exposed to a plethora of staples in music like, Janet Jackson, Ready for the World, New Edition, Chaka Khan, Luther Vandross, Anita Baker, Kanye West, and more. Learned the Trombone in school band and some piano via YouTube University. He names his Greatest Beats of All Time from 'The Inside' by 14KT feat. Tiffany Paige from The Golden Hour & 'Through the Wire' by Kanye West from The College Dropout. He names his Beatmaker/Music Producer Superheros like Kanye West, Illingsworth, Q-Tip, 14KT, J Dilla, B4Lasers, Radicule, and more. Cozy Cole G. creates music using different samplers like Native Instruments Maschine MK3 & SP404s and more.Cozy Cole G gave creator details about albums some of his like '3LBs Beat Tape Vol. 2, 'Universal Mastery', 'Need For Space' and what it was like creating inside a global pandemic. Cole G. left crazy jewels, inspiring words for Beatmakers and detailed what's in store for the rest of 2023.Cozy Cole G's Gems:1. Take your production to another level with Fiverr 2. Listen to music that feeds your soul3. Don't be scared to perform4. Build momentum and keep goingIntro Track: 'Red M3' by Kreatev from Chillhop Essentials Fall 2023 by Chillhop MusicFeatured Music: Various tracks from Cozy Cole G's Music Discography (Available Here)Social Media: @Cozycoleg Website: https://linktr.ee/colegbeatsSupport the showEdited, Mixed and Mastered by GldnmndPodcast Website Link: The Rec Show PodcastSupport the showEdited, Mixed and Mastered by GldnmndPodcast Website Link: The Rec Show PodcastNEW!!! TheRecShowPodcast Music Playlist Available Here
You might be shocked to learn that a set with a strong Food theme has a lot of Flavor Gems! We dive into this bounty of tasty cards and come out stuffed to the gills with gems to share with you. Hopefully you're satiated by this veritable feast of fairy-tale themed cards! If you enjoy our podcast, consider supporting us on Patreon at Patreon.com/TheVorthosCast, where just $1 a month gets you access to our Discord channel where Vorthoses from around the world are reacting to the incredible story unfolding every day. For $3 a month you get access to our live listen, where you can hear the unedited podcast as we record it days before it goes live!
We are taking a little time off of researching to bring you some of the wackiest news from the past week or so! Let us know what you think about the stories we covered. Are aliens real? Should a man be arrested for trying to cross the ocean in a giant hamster wheel? Want to support us? You can! Go to Patreon.com/GemsofHistoryPodcast or download the Patreon app and search for the show!
Love the movie? Read the book before it's banned! In this episode, host Sandra Abrams chats with Kristen Lopez, author of "But Have You Read the Book? 52 Literary Gems That Inspired Our Favorite Films” in association with Turner Classic Movies. Kristen knows her topic as creator of the Ticklish Business podcast and a film editor with entertainment daily, TheWrap. Film buffs will get the behind-the-scenes story of how THE THIN MAN, DUNE, and PASSING went from book to an adaptive screenplay and then beloved classic film. They also discuss the impact of the current banned book atmosphere on future screen-based works. Find the book wherever books are sold, including: Hachette Book GroupTicklish Business podcast www.thewrap.com/author/kristen-lopez/
A new MP3 sermon from Grace Audio Treasures is now available on SermonAudio with the following details: Title: Spurgeon Gems! Subtitle: Puritan Devotional Speaker: C. H. Spurgeon Broadcaster: Grace Audio Treasures Event: Devotional Date: 9/15/2023 Bible: John 3:16; Romans 8:28 Length: 49 min.
A new MP3 sermon from Grace Audio Treasures is now available on SermonAudio with the following details: Title: Spurgeon Gems! Subtitle: Puritan Devotional Speaker: C. H. Spurgeon Broadcaster: Grace Audio Treasures Event: Devotional Date: 9/15/2023 Bible: John 3:16; Romans 8:28 Length: 49 min.
Elliott quizzes Dan and Stu on cinematic treasures.We've changed how we're running FLOP TV — now all of the shows will be up until late January, so that even if you buy a season pass late in the season, you'll have access to EVERY episode until then. You can buy tickets here!Donate to the Entertainment Community Fund, to support those affected by the WGA strike.
To celebrate RAB Day 2023, Moulz & Mel are joined by @yungestilos and @Ad8AndFriends for SoundCloud Gems: A Rap Rankings Retrospective, a showcase of their favorite music discovered on and exclusive to (at least initially) the platform at its peak.
In this heartfelt episode, Dana "Truly Inspired" Martin, shares their courageous journey through a prolonged hiatus from the podcasting world, caused by a confluence of health challenges, anxiety, and depression. With raw honesty, she delves into the depths of these struggles, offering a poignant reminder of the importance of self-awareness.By listening to their own body and mind, they discovered the resilience within. Tune in to this powerful episode to gain insights into the battles that many face silently and the strength it takes to overcome them. It's a testament to the human spirit's capacity to heal and thrive.websites mentioned in episode:www.itstrulyinspiredmartin.com/eventswww.recrownyoupodcast.comwww.itstrulyinspiredmartin.comFollow @recrownyoupodcast on instagram and our host @trulyinspiredmartinDon't forget it to chime in on our community name:TRULY INSPIRED TRIBE?GEMS?BADDIES (FOR BADASSES)
How do you navigate the labyrinth of pain and loss and find a spark of hope? How do you transform personal tragedy into a beacon of light for others? These are questions that our guest today, Kat Morris, faced when she lost her vivacious daughter, Kandis, a passionate Marine Osprey pilot, to stage four colon cancer. Kat's story is both heartbreaking and inspiring. From recounting Kandis' vibrant spirit and love for leadership, community service, and sports, to describing her harrowing battle with cancer, Kat's account provides a profound connection for anyone who has experienced a similar loss.Kat illuminates us on her journey through grief, likening it to a black hole, and shares how she embarked on a path of self-discovery, finding solace in spiritual connections and research about grief. Her recounting of a dream where Kandis visits her is heart-rending and resonates deeply, revealing how her spiritual bond with her daughter has grown since her passing. Kat's resilience and unyielding spirit are truly remarkable, pulling her from the depths of despair to transform her grief into something purposeful and empowering.Kat's dedication and love for her late daughter transcends into the creation of the Captain Kandis Cookie Ruiz Foundation (CKCRF), a nonprofit organization that offers comprehensive support to military personnel, civilians, and rugby athletes battling cancer. Her commitment to honoring Kandis' memory extends to other families navigating a similar journey, reinforcing her daughter's legacy of leadership and community service. Tune in to hear Kat's raw and breathtaking testimony of love, loss, and resilience, and discover how her spiritual connection with Candace illuminates her path through grief.I'm excited to announce a new resource I'm very proud of. This guide outlines the four daily practices I discovered on my grief journey. These techniques have helped dozens of my clients. Get it free today.GEMS- 4 Steps To Go From Grief To Joy I've been studying Near Death Experiences for many years now. I am 100% convinced they are real. In this short, free ebook, I not only explain why I believe NDEs are real, I share some of the universal secrets brought back by people who have had them.https://www.grief2growth.com/ndelessonsSupport the show
Whether it's planning for how the oil is laid in a bowling alley or road closures that impede EMS, Emergency Action Plans come in many shapes and sizes. In this BOC IRL Episode, ATs share their stories of utilizing and planning their EAPs Featuring stories from Gems from Jen, Haley L, Francesca P, Justin N, MVP Nicolette, Meghan M, Chris C, & many more! -- AT CORNER FACEBOOK GROUP: https://www.facebook.com/groups/atcornerpodcast Instagram, Website, YouTube, and other links: atcornerds.wixsite.com/home/links EMAIL US: firstname.lastname@example.org SAVE on Medbridge: Use code ATCORNER to get $150 off your subscription SAVE on Precision AT: Use code ATCORNER for 15% off all home study courses Music: Jahzzar (betterwithmusic.com) CC BY-SA -- -Sandy & Randy
V5EP38: "Masked Avengers" And another one! The HHM boys are back to discuss the posibility of Robert Downey Jr. returning to the MCU, Tony Stark and Emma Frost tie the knot, Daredevil Born Again no longer in release schedule, Puff gives publishing back to Bad Boy artists and B.G. is finally released after 11 years. They also get into Drake announcing his official album release date and Lauryn Hill's Miseducation Tour. In the Droppin' Gems segment they focus on Marvel and Non-Marvel alter egos in Hip Hop. and E-Ray blesses us with some upcoming events. All of that and much more on an all new episode of Hip Hop Marvels Podcast! "WE GOT IT LOCKED FROM THE BLOCK TO THE COMIC SHOP!"FANTASTIC 4:1. Busta Rhymes & Coi Leray - Luxury Life2. DJ Muggs ft. CeeLo - Joker's Wild3. 38 Spesh & Conway The Machine ft. Lloyd Banks - Latex Gloves4. Ghostface Killah - Slept On Tony (Original Version)SPONSOR:Hook & Kee Creations LLC. (Sanford, NC)"Bringing You A Little Taste Of New Orleans, One Bite At A Time!"https://www.facebook.com/hookandkeecreationsHookandKee@gmail.com(919) 537-9676LISTEN-SHARE-RATE-SUBSCRIBE: Pandora, Apple Podcasts, Amazon Music, Spotify, Google Podcasts, Audible, TuneIn, iHeartRadio, Castbox, Stitcher, Podcast Addict & anywhere else you get your podcasts!Have a question, comment or suggestion? Email us: email@example.comHIP HOP MARVELS is movement focusing on the impact Marvel Comics/Entertainment has on the culture of Hip Hop and vice-versa. Your friendly neighborhood plug for all things Hip Hop and Marvel! "WE GOT IT LOCKED FROM THE BLOCK TO THE COMIC SHOP!"Creator/Executive Producer/Host: DJ Dub Floyd (@djdubfloyd)Producer/Director/Sound: Hasani Wizzard (@dovestatus) Director/Music/Host: Pat Mulli (@southerndrawl_410_side_ent)Co-Host: Rick 0378 (@braille378)Co-Host: E-Ray (@lionheadcircle)Co-Host: Double T (@t91t91)Co-Host: JigPool (@jigpoolnc) Correspondent/Co-Host: Brandess (@8tiesbaby82)HHMP Intro: Bash Brothers - Precyce Politix (@cyceboogie), Mallz (@mallzini), Sharp Cuts (@sharpcutsofficial)Music: Sharp Cuts (@sharpcutsofficial), Tecknowledgy (@teckbeats), Kreatev (@kreatev)www.hiphopmarvels.comTwitter: @hiphopmarvelsIG: @hiphopmarvelsFB: https://www.facebook.com/hiphopmarvelsYouTube: https://www.youtube.com/@hiphopmarvels
Have you ever freaked out a tiny bit at the idea of AI for your online course? Today we're diving deep into the non-scary ways to sprinkle a bit of that AI magic without fearing a Skynet scenario.
Preventative maintenance with Emily SchmittAs of February 2, 2021 - Emily Schmitt, a third-generation family member, was been promoted to Chief Administrative Officer and General Counsel. She leads the legal, human resources, communications, strategic planning, and administrative functions of the company. Emily earned a bachelor's degree in business management from Iowa State University in 2008, and went on to earn a Juris Doctorate from the University of Iowa College of Law with high honors in 2011. After graduating she began working for Sukup Manufacturing Co. in Sheffield, Iowa as corporate counsel.Schmitt is the granddaughter of founder Eugene Sukup and daughter of current president and CEO, Steve Sukup.As the only lawyer at Sukup — which employs more than 500 people — she plays a vital role providing legal counsel at all levels of the company.When said out loud, what does preventative maintenance mean to you?In your role, why is it important to be thinking ahead?How far do you see yourself thinking ahead?Does that change depending on the situation or time of year?Emily Schmitt has fond memories of walking to the Sheffield, Iowa, office after school, playing good-natured pranks on staff members who felt like family. How did growing up around the company help you gain perspective for the role you currently have?Would you compare the childhood perspective you gained to that of a kid growing up on a farm?TELL US ABOUT THE FAMILY MEMBERS INVOLVED AT SUKUP AND HOW YOU WORK TOGETHER.I work with my husband on a daily basis. My two kids are known as the recycling directors. Before COVID, they would take a wagon around and fill it up with everybody's recycling and collect some candy. My brother-in-law, my dad – oftentimes we work five days a week. What is the key to keeping family and work tougher but separate? We have listeners that right in wanting the solution to not being mad or resentful at a parent or a sibling involved in the farm or business.DID YOU ALWAYS KNOW YOU WANTED TO COME BACK TO THE COMPANY FOR YOUR CAREER?What would you say to our listener who is currently in school or college or working off the farm that is trying to find their fit in the family business?In your role as CHIEF ADMINISTRATIVE OFFICER AND GENERAL COUNSEL. Is this where you were able to have a real focus on the future of the company and what needs to get taken care of now for growth to happen in the future?In 2019 Emily was named to the business record 40 under 40. One of the main reasons what the preventative maintenance she does with the Sukup Employees.Giving employees purpose. Getting to know the employees further ingrains my dedication to them and the company. An interesting fact about Schmitt: She created a jewelry line in high school, Gems by Em. She is using jewelry to help residents of Haiti.What do you do to tackle the tasks each day knowing that each day will be different?What is your key to prioritizing?How does this help with stress and your mental health?How do you get things done quickly when relying on other people? Do you have any tricks that have helped you become better at thinking further ahead?What do you think about the phrase “Don't assume you know what others need”Don't be afraid to ask for feedback or insightPerseveranceThe business world is a highly unpredictable and stressful environment. It's all up to specific individuals and their ability to learn and reach their goals despite the uncertainty around them. Anything else you'd like to share with our listeners?What do you enjoy most about working with and for farmers?Summary & Challenge
Undrafted players who could have a fantasy impact! On today's fantasy football podcast, players to stash now before they become hot waiver wire targets! Plus, George Kittle backup options, NFL News, and greatest fears for the 2023 fantasy football season! Manage your redraft, keeper, and dynasty fantasy football teams with the #1 fantasy football podcast. --- Fantasy Football Podcast for September 5th, 2023. Connect with the Fantasy Footballers Podcast: Subscribe on YouTube Visit us on the Web Support the Show Follow on Twitter Follow on Instagram Join our Discord Check out today's sponsors: News & Notes presented by USAA. Visit https://USAA.com/Insurance Welcome to the Waiver Wire, presented by NFL Sunday Ticket on YouTube and YouTube TV. Visit youtube.com/fantasyfootballers Learn more about your ad choices. Visit podcastchoices.com/adchoices